Shattuck Labs Inc. (STTK)
0.81
-0.17 (-17.65%)
At close: Apr 03, 2025, 3:07 PM
Company Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma.
The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs Inc.
| Country | United States |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Dr. Taylor H. Schreiber M.D., Ph.D. |
Contact Details
Address: 500 West 5th Street Austin, Texas United States | |
| Website | https://www.shattucklabs.com |
Stock Details
| Ticker Symbol | STTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001680367 |
| CUSIP Number | 82024L103 |
| ISIN Number | US82024L1035 |
| Employer ID | 81-2575858 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Andrew R. Neill M.B.A. | Chief Financial Officer |
| Casi DeYoung | Chief Business Officer |
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs |
| George Fromm Ph.D. | Co-Chief Scientific Officer |
| Kelli Collin M.S. | Senior Vice President of Quality |
| Suresh de Silva Ph.D. | Co-Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 424B5 | Filing |
| Mar 27, 2025 | S-8 | Filing |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 28, 2025 | 4 | Filing |
| Jan 28, 2025 | 4 | Filing |
| Jan 28, 2025 | 4 | Filing |
| Jan 28, 2025 | 4 | Filing |
| Jan 28, 2025 | 4 | Filing |